PIPages
Labs

Charles M Perou

University of North Carolina at Chapel Hill, NC·Genetics

Dr. Charles M.

Fields

Genetics

Topics

breast cancer

metastasis

machine learning

Grants
4 known grants, through Jul 2030

What they work on

  1. Identify the molecular determinants of organ-specific metastasis in breast cancer.
  2. Characterize the interaction between established tumors and their local microenvironment.
  3. Utilize machine learning to analyze complex datasets of human and mouse models.
  4. Uncover critical crosstalk that sustains tumor growth in metastatic sites.
  5. Develop potential therapeutic interventions based on research findings.

More about the research

Perou's lab at the University of North Carolina Chapel Hill focuses on understanding how breast cancer cells spread to different organs in the body. By studying the molecular and cellular mechanisms involved in this process, particularly in various subtypes of breast cancer, the lab aims to identify why certain tumors prefer to metastasize to certain organs. The research combines data from human samples and mouse models with advanced techniques to uncover potential new treatments for metastatic breast cancer.

Known grants

From NIH and NSF research grants. Labs often have other funding we can't see.

Elucidating the molecular mechanisms of metastasis organ tropism

NIH · Aug 2025 – Jul 2030

Project 3: Development of Novel Therapies and Biomarkers for TNBC Patients

NIH · Aug 1997 – Aug 2029

SPORE in Breast Cancer

NIH · Aug 1997 – Aug 2029

Closest labs

Benjamin Spike

University of Utah, UT·Biology

Track how CRIPTO (CR1) drives cell state changes at different stages of breast cancer metastasis, using mouse transplant models with patient-derived cancer cells, bioengineered systems and single-cell RNA sequencing.

Rebecca Aft

Washington University in St Louis, MO·Medicine & Clinical Research

Evaluate whether an 8-gene bone marrow test for disseminated tumor cells predicts distant metastasis in TNBC patients treated with carboplatin, paclitaxel and nivolumab, with or without cabiralizumab, in a phase II trial.

Sanchita Bhatnagar

University of California-Davis, CA·Medicine & Clinical Research

Screen TRIM37 gene variants already identified in African American women for anoikis resistance, the ability of cancer cells to survive after detaching, and compare how risk and reference alleles of TRIM37 behave biologically.

The school

University of North Carolina at Chapel Hill: 72 labs on PI Pages, $1.6B a year on research, 523 research doctorates a year.

More about University of North Carolina at Chapel Hill

Reach out

A start for your email. Fill in the brackets.